The Phase III SOLAR-1 trial showed benefit of alpelisib plus fulvestrant in those PIK3CA-mutated HR+ HER2- advanced BC patients who had progressed on or after prior aromatase inhibitor therapy mutation [14]. This evidence concerns the gene CYP19A1 and breast cancer.